scroll down
Global API CDMO Company
Walking with partners,
Creating value

Technology-driven gene therapy CDMO
from oligonucleotide to xRNA

View our Science & Technology

ST PHARM NEWS
ST Pharm Enhances Stakeholder Communication with Release of First Sustainability ReportST Pharm Enhances Stakeholder Communication with Release of First Sustainability ReportJun 24, 2025
ST Pharm Joins TIDES USA 2025, Ramping Up Efforts in North American RNA Therapeutics MarketST Pharm Joins TIDES USA 2025, Ramping Up Efforts in North American RNA Therapeutics MarketMay 26, 2025
[Notice] Completion of Patient Enrollment for Interim Analysis of Phase 2a Study of STP0404 (Pirmitegravir)May 21, 2025
Global API CDMO Company
Walking with Partners, Creating Value

30+years

Track record

40+

Global CDMO Project

6.4mole

Oligo CDMO Capacity ('22)

1.0kg / year

mRNA CDMO Capacity
Media Focus
ST PHARM Cuts Joint Research Deal with Multiverse Pharma in the U.S.Feb 24, 2023
ST PHARM, signs $9.2million contract to supply MRI contrast medium raw materialsJan 11, 2023
IR Library
Stock Information

KRWKOSDAQ

(%)

Location

70km (43 mile)

40km (25 mile)

40km (25 mile)

51km (32 mile)

Seoul Office

Seoul Office

7F, I Park Tower Bldg., Yeongdongdae-ro 520, Gangnam-gu, Seoul
06170

  • Marketing and sales
  • Regulatory affairs
  • Management

Sihwa campus

Sihwa campus

231 Hyeomnyeok-ro, Siheung-si, Gyeonggi-do
15086

  • cGMP Manufacturing
  • QC/QA
  • R&D

Banwol campus

Banwol campus

171 Haean-ro, Danwon-gu, Ansan-si, Gyeonggi-do
15610

  • cGMP Manufacturing
  • QC/QA
  • R&D

Incheon Airport

© 2026 ST Pharm. All rights reserved.

We care about your privacy

This site uses essential cookies necessary for the operation of the service and for maintaining your language preferences. For more information, please review our Privacy Policy and Terms of Service.